Alice P. Chen

National Institutes of Health — United States

Medicine · Health Sciences

66h-index18.6kcitations757works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(167), Lung Cancer Treatments and Mutations(125), Cancer Genomics and Diagnostics(102), DNA Repair Mechanisms(79), Cancer therapeutics and mechanisms(78)

Publications754 total

Efficacy of Bidirectional Paclitaxel plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single Institution Analysis of Two Phase II Clinical Trials
Annals of Surgical Oncology·2026· 1 citedOpen Access
Supplementary Figure 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Data from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Data 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Clinical benefits of selumetinib in adults with neurofibromatosis type 1 – Authors' reply
The Lancet·2025
Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in <i>CCND1</i>, <i>2</i>, or <i>3</i> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
2025Open Access
Perceptions of Sickle Cell Disease in Sierra Leone
Global Journal of Health Science·2025· 1 citedOpen Access
Editorial: Case reports in tumor genomics and ctDNA in precision medicine
Frontiers in Medicine·2025Open Access
Assessing Pediatric Endodontic Referrals to University-Based Clinics: A Retrospective Chart Review
Dentistry Journal·2025Open Access
Dual-function engineered bacteria remodel AML tumor microenvironment via IL-12 delivery and adenosine depletion to sustain NK cell immunity
Blood·2025
Abstract A016: cfDNA fragmentome predicts cancer treatment response similarly to mutant allele fraction
Molecular Cancer Therapeutics·2025
Supplementary Figure 3 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Table 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Data from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Table 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
page 1 of 38Next →

Frequent Co-authors

James H. Doroshow(15), Larry Rubinstein(13), Barbara A. Conley(12), Shivaani Kummar(11), Robert J. Kinders(10), Lisa M. McShane(10), P. Mickey Williams(9), Lyndsay N. Harris(9), Ralph E. Parchment(8), Keith T. Flaherty(8), Robert J. Gray(8), Shuli Li(8), David R. Patton(8), Edith P. Mitchell(8), James A. Zwiebel(8), Carlos L. Arteaga(8), Jiuping Ji(7), Stanley R. Hamilton(7), Peter J. O’Dwyer(7), Joseph E. Tomaszewski(5)